RT Journal Article
SR Electronic
T1 Deep Learning-based Prediction of Early Cerebrovascular Events after Transcatheter Aortic Valve Replacement
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.10.21263380
DO 10.1101/2021.09.10.21263380
A1 Okuno, Taishi
A1 Overtchouk, Pavel
A1 Asami, Masahiko
A1 Tomii, Daijiro
A1 Stortecky, Stefan
A1 Praz, Fabien
A1 Lanz, Jonas
A1 Siontis, George CM
A1 Gräni, Christoph
A1 Windecker, Stephan
A1 Pilgrim, Thomas
YR 2021
UL http://medrxiv.org/content/early/2021/09/14/2021.09.10.21263380.abstract
AB Background Cerebrovascular events (CVE) are one of the most feared complications of transcatheter aortic valve replacement (TAVR). CVE appear difficult to predict due to their multifactorial origin incompletely explained by clinical predictors. We aimed to build a deep learning-based predictive tool for TAVR-related CVE.Methods Integrated clinical and imaging characteristics from consecutive patients enrolled into a prospective TAVR registry were analysed. CVE comprised any strokes and transient ischemic attacks. Predictive variables were selected by recursive feature reduction to train an autoencoder predictive model. Area under the curve (AUC) represented the model’s performance to predict 30-day CVE.Results Among 2,279 patients included between 2007 and 2019, both clinical and imaging data were available in 1,492 patients. Median age was 83 years and STS score was 4.6%. Acute (<24 hours) and subacute (day 2-30) CVE occurred in 19 (1.3%) and 36 (2.4%) patients, respectively. The occurrence of CVE was associated with an increased risk of death (HR [95%CI]: 2.62 [1.82-3.78]). The constructed predictive model uses less than 107 clinical and imaging variables and has an AUC of 0.79 (0.65-0.93).Conclusions TAVR-related CVE can be estimated using a deep learning-based predictive algorithm. The model was implemented online for broad usage. (https://www.welcome.alviss.ai/#/cvecalculator).Competing Interest StatementDr. Overtchouk is the CEO of ALVISS.AI SAS. Dr. Windecker serves as unpaid advisory board member and/or unpaid member of the steering/executive group of trials funded by Abbott, Abiomed, Amgen, Astra Zeneca, BMS, Boston Scientific, Biotronik, Cardiovalve, Edwards Lifesciences, MedAlliance, Medtronic, Novartis, Polares, Sinomed, V-Wave and Xeltis, but has not received personal payments by pharmaceutical companies or device manufacturers. He is also member of the steering/excecutive committee group of several investigated-initiated trials that receive funding by industry without impact on his personal remuneration. Dr. Windecker is an unpaid member of the Pfizer Research Award selection committee in Switzerland. Dr. Pilgrim reports research grants to the institution from Edwards Lifesciences, Boston Scientifc and Biotronik, personal fees from Biotronik and Boston Scientific, and other from HighLife SAS. Dr. Okuno reports speaker fees from Abbott. All other authors have no relationships relevant to the contents of this article to disclose.Funding StatementNo funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The registry is approved by the Bern cantonal ethics committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article is held at the Clinical Trials Unit of the University of Bern, Switzerland. Data can be made available to external investigators upon request to the corresponding author with permission of the institution, according to local regulations.